You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
中國生物製藥(01177.HK)旗下抗腫瘤藥「甲磺酸伊馬替尼膠囊」獲一致性評價
阿思達克 08-01 16:55

中國生物製藥(01177.HK)公布,附屬公司正大天晴藥業集團股份有限公司的抗腫瘤藥「甲磺酸伊馬替尼膠囊」(商品名稱「格尼可」)獲得國家藥品監督管理局批准通過仿製藥質量和療效一致性評價。

甲磺酸伊馬替尼是一種Bcr-Abl酪氨酸激(酉每)抑制劑,用於治療慢性髓性白血病(CML)的急變期、加速期或干擾素治療失敗的慢性期患者。

公司指,通過了一致性評價,格尼可獲確認其品質和療效與原研藥一致,可實現原研藥的臨床替代,能為患者提供優質低價的用藥選擇,同時也使該產品在市場拓展、醫保支付等層面上可獲得更多優勢。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account